ANI Pharmaceuticals launches generic Baclofen Oral Suspension, entering a $39M annual market.

ANI Pharmaceuticals has announced the launch of Baclofen Oral Suspension, a generic version of Fleqsuvy®, with US annual sales of approximately $39 million. This marks another entry for ANI into a rapidly growing limited competition market. ANI Pharmaceuticals is a diversified biopharmaceutical company serving patients with high-quality branded and generic prescription pharmaceuticals.

April 09, 2024
3 Articles

Further Reading